COPAXONE Drug Patent Profile

When do Copaxone patents expire, and when can generic versions of Copaxone launch?

Copaxone is a drug marketed by Teva Pharms Usa and is included in one NDA.

The generic ingredient in COPAXONE is glatiramer acetate. There are five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the glatiramer acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Copaxone

A generic version of COPAXONE was approved as glatiramer acetate by MYLAN on October 3^rd, 2017.

Summary for COPAXONE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	28
Clinical Trials:	52
Drug Prices:	Drug price information for COPAXONE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for COPAXONE
What excipients (inactive ingredients) are in COPAXONE?	COPAXONE excipients list
DailyMed Link:	COPAXONE at DailyMed

See drug prices for COPAXONE

See drug sales revenues for COPAXONE

Recent Clinical Trials for COPAXONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Kansas Medical Center	Phase 1
Genzyme, a Sanofi Company	Phase 3
Teva Pharmaceutical Industries, Ltd.	Phase 4

See all COPAXONE clinical trials

Paragraph IV (Patent) Challenges for COPAXONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COPAXONE	Injection	glatiramer acetate	40 mg/mL, 1 mL pre- filled syringe	020622	2	2014-02-26
COPAXONE	Injection	glatiramer acetate	20 mg/mL, 1mL pre- filled syringe	020622	1	2007-12-27

US Patents and Regulatory Information for COPAXONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996		DISCN	Yes	No
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	AP	RX	Yes	Yes
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	AP	RX	Yes	Yes

Expired US Patents for COPAXONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	6,054,430
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,620,847
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	5,981,589
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,342,476

International Patents for COPAXONE

See the table below for patents covering COPAXONE around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3199172
European Patent Office	2949335
Norway	324528
Cyprus	1118529

Supplementary Protection Certificates for COPAXONE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0762888	90987	Luxembourg
0762888	C300096	Netherlands		PRODUCT NAME: GLATIRAMEER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET ACETAAT; NAT. REGISTRATION NO/DATE: RVG 26748 20010927: FIRST REGISTRATION: GB PL 10921/0019 20000809
0762888	C300251	Netherlands		PRODUCT NAME: GLATIRAMEER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET ACETAAT; NATL. REGISTRATION NO/DATE: RVG 26748 20010927; FIRST REGISTRATION: GB PL 10921/0019 20000809

Market Dynamics and Financial Trajectory for COPAXONE

Last updated: February 19, 2026

What is COPAXONE and How Does It Fit in the Multiple Sclerosis Market?

COPAXONE (glatiramer acetate) is a disease-modifying therapy (DMT) approved for relapsing forms of multiple sclerosis (MS). It has been marketed by Teva Pharmaceutical Industries Ltd. since 1996, with a primary focus on the United States, Europe, and other major markets.

The drug's mechanism involves immune modulation, reducing MS relapses. It is administered via subcutaneous injection, typically daily or three times weekly, depending on formulation.

The MS DMT landscape is highly competitive. Key players include:

• Biogen (Tecfidera, Avonex)
• Novartis (Gilenya, Mayzent)
• Roche/Chugai (Ocrevus)
• Teva (COPAXONE)
• Merck (Rebif)

COPAXONE holds a significant market share in the long-standing MS treatment segment but faces challenges from newer oral and infusion therapies.

How Has the Market for COPAXONE Evolved?

Initial dominance: COPAXONE was among the first oral DMTs for MS, capturing over 40% of the US market peak in 2008.

Market decline: Competition from oral therapies like Tecfidera (2013), Gilenya (2014), and Mavenclad (2019), reduced COPAXONE's share.

Patent expiration impact: Teva’s patent protection expired in 2015, allowing biosimilars and generics to enter the market. The first generic version launched in the US in 2017, leading to a sharp price decline.

Pricing: COPAXONE's list price was approximately $6,000 per month in 2015. Generic versions prompted a reduction to ~$3,000, with some markets reporting even lower prices.

Market share shifts: By 2022, COPAXONE's contribution to Teva’s total MS portfolio sales dropped below 20%. Sales of the brand-name drug declined from over $3 billion (2014) to less than $1 billion (2022).

What Are the Current Financial Trends for COPAXONE?

Year	Sales (USD billions)	Market Share	Notes
2014	3.2	40% (MS segment)	High due to patent exclusivity
2017	2.0	30%	First generic launched in US
2020	1.2	15%	Biosimilars gained traction
2022	0.8	<20%	Ongoing patent litigation and biosimilar competition

Teva’s global MS sales declined approximately 25% from 2017 to 2022, with COPAXONE accounting for a shrinking portion.

How Might Patent and Regulatory Changes Affect COPAXONE?

Patent expiry in key markets promotes biosimilar competition, which erodes revenue and affects profit margins. Legal disputes over patents delay biosimilar market entry in some regions but do not prevent it globally.

In 2020, Teva registered a new formulation, COPAXONE 40 mg, to enhance compliance and extend the product cycle. The formulation received approval in the US in 2019, with commercialization efforts starting in 2020.

Regulatory approvals in Europe for generic glatiramer acetate products have increased, enabling wider market access for competitors.

What Are Future Market Opportunities and Risks for COPAXONE?

Opportunities:

• Transition to newer formulations (e.g., 40 mg) to extend lifecycle.
• Potential for combination therapies targeting MS.
• Expansion in emerging markets with increasing MS prevalence.

Risks:

• Accelerated biosimilar entry, especially post-2017 in the US and Europe.
• Competition from oral and infusion therapies with better efficacy profiles or dosing convenience.
• Patent challenges and legal disputes within key jurisdictions.

How Do Competitive Dynamics Impact Revenue Projections?

Analysts expect COPAXONE revenues to stabilize at around $500 million to $700 million annually over the next three years, assuming no major legal delays for biosimilar entry. Market share decline will likely slow as Teva implements strategic pricing and marketing tactics for the 40 mg formulation.

Total MS treatment sector sales are projected to grow at a compound annual growth rate (CAGR) of 2-3%, driven by demographic factors, increasing diagnosis rates, and new treatment options, which pressure traditional therapies like COPAXONE.

Key Takeaways

• COPAXONE remains a relevant MS therapy but faces substantial revenue erosion due to biosimilar competition.
• Patent expirations and legal disputes significantly influence market dynamics.
• Newer formulations may extend its market presence but with limited growth potential.
• The overall MS market is expanding, providing opportunities in emerging regions.
• Revenue declines are expected to continue unless strategic shifts or regulatory changes occur.

FAQs

1. When did COPAXONE first lose patent protection?
   The original patent expired in 2015, leading to biosimilar market entries starting in 2017.

2. What is the primary competitive threat to COPAXONE?
   Biosimilar versions of glatiramer acetate and newer oral therapies such as Tecfidera and Gilenya.

3. What is the expected revenue for COPAXONE over the next five years?
   Approximately $500 million to $700 million annually, assuming current market trends and legal landscapes.

4. Are there regulatory hurdles affecting biosimilar entry?
   Yes. Patent litigation, regulatory delays, and market access restrictions can slow biosimilar launches.

5. What initiatives has Teva taken to sustain COPAXONE's market share?
   Development of the 40 mg formulation, increased marketing efforts, and expansion into emerging markets.

---

References:

[1] IMS Health. (2022). Pharmaceutical Market Intelligence.
[2] Teva Pharmaceutical Industries Ltd. Annual Reports. (2014-2022).
[3] FDA. (2019). Approval of Copaxone 40 mg/mL.
[4] European Medicines Agency. (2020). Regulatory assessments for glatiramer acetate biosimilars.
[5] MarketWatch. (2023). MS drug market outlook and forecast.